Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH Interest Income

Income earned on cash, deposits, and investments held by the company.

Accendra Health, Inc.NYSE: ACH

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income remains negative

Q1 FY2026 interest income was $0, compared with $0 a year earlier. Trailing-twelve-month interest income was $0.

Context

  • Interest income amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest income increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Income vs competitors

How ACH compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Interest income amounts to 0.0% of revenue for ACH, versus a peer median of 3.7%.
ACH Competitors
Interest Income for ACH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$17.35M USD-14.3%+61.7%—
BIOABioAge Labs, Inc.LTM Mar 2026$12.64M USD+4.9%+204.2%122.5%
CGCCanopy Growth CorporationLTM Mar 2026CA$11.15M CAD+26.5%-25.6%3.6%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$6.99M USD-14.1%—83.5%
OMOutset Medical, Inc.LTM Mar 2026$6.96M USD-19.5%+31.1%5.9%
CABACabaletta Bio, Inc.LTM Mar 2026$5.62M USD-34.1%+73.0%—
SGHTSight Sciences, Inc.LTM Mar 2026$1.86M USD——2.3%
ACHAccendra Health, Inc.LTM Mar 2026$0 USD——0.0%
HITIHigh Tide Inc.LTM Apr 2026CA$0 CAD——0.0%
CVRXCVRx, Inc.LTM Mar 2026$0 USD——0.0%
EDITEditas Medicine, Inc.LTM Mar 2026-$1.51M USD-112.9%+14.6%3.9%
Peer median (excluding ACH) —-14.3%+46.4%3.7%

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.79B9.96B10.33B10.7B2.76B
Cost of Revenue8.27B8.13B8.21B8.48B1.56B
Gross Profit1.51B1.83B2.13B2.22B1.2B
Gross Margin15.5%18.3%20.6%20.7%43.5%
Research & Development12.1M0000
Selling, General & Admin1.08B1.55B1.81B1.91B1.05B
Operating Expenses1.14B1.68B2.02B2.43B1.05B
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
EBITDA415.47M368.45M390.57M51.22M364.68M
EBITDA Margin4.2%3.7%3.8%0.5%13.2%
Operating Income368.47M142.91M104.51M(207.77M)150.16M
Operating Margin3.8%1.4%1.0%-1.9%5.4%
Interest Income00000
Interest Expense48.09M128.89M157.92M143.8M129.2M
Other Income / Expenses(91.72M)(132.02M)(159.23M)(149.59M)(252.11M)
Income Before Tax276.75M10.89M(54.73M)(357.36M)(101.95M)
Pre-Tax Margin2.8%0.1%-0.5%-3.3%-3.7%
Income Tax Expense55.17M(11.5M)(13.43M)5.33M729K
Net Income221.59M22.39M(41.3M)(362.69M)(1.1B)
Net Margin2.3%0.2%-0.4%-3.4%-39.8%
EPS (Basic)3.050.30(0.54)(4.73)(14.31)
EPS (Diluted)2.940.29(0.54)(4.73)(14.31)
Weighted Avg Shares72.74M74.5M75.79M76.74M76.9M
Weighted Avg Shares (Diluted)75.49M76.22M75.79M76.74M76.9M

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.